Onkologie. 2019:13(5):205-208 | DOI: 10.36290/xon.2019.039

What is new in radiotherapy for bladder cancer

Pavel Krupa
Klinika radiační onkologie LF MU a MOÚ, Brno

The position of radiotherapy in bladder cancer treatment is primarily a alternative method in patients who are not candidates for
radical cystectomy. It stays as basic palliative method as well.

Keywords: radiotherapy, bladder cancer

Published: October 20, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krupa P. What is new in radiotherapy for bladder cancer. Onkologie. 2019;13(5):205-208. doi: 10.36290/xon.2019.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Foroudi F, Wilson L, Bressel M, et al. A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer. Radiat Oncol, 2012; 7: 111 Go to original source... Go to PubMed...
    2. Pos F, Bex A, Dees-Ribbers HM, et al. Lipiodol injection for target volume delineation and image guidance during radiotherapy for bladder cancer. Radiother Oncol, 2009; 93: 364-367. Go to original source... Go to PubMed...
    3. Foroudi F, Wong J, Haworth A, et al. Offline adaptive radiotherapy for bladder cancer using cone beam computed tomography. J Med Imaging Radiat Oncol, 2009; 53: 226-233. Go to original source... Go to PubMed...
    4. Pos FJ, Hulshof M, Lebesque J, et al. Adaptive radiotherapy for invasive bladder cancer: a feasibility study. Int J Radiat Oncol Biol Phys, 2006; 64: 862-868. Go to original source... Go to PubMed...
    5. Vestergaard A, Muren LP, Sondergaard J, et al. Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: a dose accumulation comparison. Radiother Oncol, 2013; 109: 457-462. Go to original source... Go to PubMed...
    6. Tuomikoski L, Collan J, Keyrilainen J, et al. Adaptive radiotherapy in muscle invasive urinary bladder cancer-an effective method to reduce the irradiated bowel volume. Radiother Oncol, 2011; 9: 61-66. Go to original source... Go to PubMed...
    7. Foroudi F, Wong J, Kron T, et al. Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys, 2011; 81: 765-771. Go to original source... Go to PubMed...
    8. Murthy V, Master Z, Adurkar P, et al. 'Plan of the day' adaptive radiotherapy for bladder cancer using helical tomotherapy. Radiother Oncol, 2011; 99: 55-60. Go to original source... Go to PubMed...
    9. Pos FJ, Hart G, Schneider C, et al. Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys, 2006; 64: 1168-1173. Go to original source... Go to PubMed...
    10. Nowak-Sadzikowska J, Jakubowicz J, Skora T, et al. Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer - clinical outcome. Contemp Oncol (Pozn), 2013; 17: 302-306. Go to original source... Go to PubMed...
    11. Yavuz AA, Yavuz MN, Ozgur GK, et al. Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer. Int J Radiat Oncol Biol Phys, 2003; 56: 734-745. Go to original source... Go to PubMed...
    12. Kouloulias V, Tolia M, Kolliarakis N, et al. Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer. Int Braz J Urol, 2013; 3: 77-82. Go to original source... Go to PubMed...
    13. Ghate K, Brennan K, Karim S, et al. Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. Radiother Oncol, 2018; 127: 136-142. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.